NCT00037206View on ClinicalTrials.gov

A Safety & Effectiveness Study of Intravenous Anidulafungin With AmBisome® for Treatment of Invasive Aspergillosis (IA).

PHASE2/PHASE3CompletedINTERVENTIONAL

Enrollment

30

Participants

Timeline

Start Date

May 31, 2002

Study Completion Date

February 28, 2003

Conditions

Aspergillosis

Interventions

DRUG

Anidulafungin, VER002

Trial Locations (1)

19406

Versicor, Inc., King of Prussia

Sponsors

Lead Sponsor

Collaborators (1)

Vicuron Pharmaceuticals

All Listed Sponsors

collaborator

Vicuron Pharmaceuticals

INDUSTRY

lead

Pfizer

INDUSTRY